news
CEPI offers $140 million to support research on COVID-19 vaccines
CEPI has opened a new funding opportunity, providing up to $140 million to support additional clinical research on COVID-19 vaccines.
List view / Grid view
Covid-19
news
Valneva begins manufacturing its inactivated, adjuvanted COVID-19 vaccine
The company announced that the Phase I/II trial for VLA2001 is now fully enrolled and that it has begun manufacturing the vaccine candidate on an industrial scale.
news
Study finds some antibody therapies are not effective against new COVID-19 variants
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.
news
Vaccine delivered via skin scarification could help fight respiratory diseases
According to a new study, vaccines delivered via skin scarification were better at inducing T cell activity in pre-clinical animal models.
news
Lilly’s antibody combo reduces COVID-19 hospitalisations and risk of death by 70 percent
Data from a Phase III trial shows high-risk patients treated with bamlanivimab and etesevimab were 70 percent less likely to be hospitalised due to COVID-19.
news
REGEN-COV prevents symptomatic COVID-19 infections, finds analysis
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.
news
Moderna COVID-19 vaccine successful against emerging variants, study shows
Results from in vitro neutralisation studies have shown that Moderna's COVID-19 vaccine is effective against emerging strains of SARS-CoV-2.
news
Desidustat prevents development of ARDS in Phase II COVID-19 trial
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
news
COVAX to purchase up to 40 million COVID-19 vaccine doses from Pfizer and BioNTech
Through COVAX, doses of the Pfizer-BioNTech vaccine will be provided at a not-for-profit price for 92 low- and lower-middle-income countries.
news
Merck to discontinue development of COVID-19 vaccine candidates
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-300x278.jpg)
![Vial labelled heparin. [Credit: SamaraHeisz5 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Heparin-scaled.jpg)
news
Increased heparin dose reduces need for life support in hospitalised COVID-19 patients
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
news
Fire at Serum Institute of India, production site of COVID-19 vaccine
Reports have said five people have been killed in a fire at the Serum Institute of India, where the Oxford-AstraZeneca COVID-19 vaccine is being made.
news
President Biden announces intention for US to remain member of WHO
The President of the US, Joe Biden, has written a letter to the UN announcing his intention for the country to remain a part of the WHO.
news
Pfizer COVID-19 vaccine effective against B.1.1.7 variant from UK
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
news
Phase II trial to establish whether alisporivir can prevent COVID-19 progression
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
